TDC
MRNS

Thompson Davis & Co’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Thompson Davis & Co’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,250
Closed -$23K – 1197
2017
Q1 		$23K Buy
+3,250
New +$17.5K 0.03% 448

Other funds holding MRNS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thompson Davis & Co's MRNS Position: Q2 2017 in Review

Thompson Davis & Co sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2017, closing a stake of 3,250 shares — an estimated $23K sold.

Thompson Davis & Co first reported a position in MRNS in Q1 2017 and held it in 1 quarter. The position peaked at $23K in Q1 2017. 24 funds tracked by Wall St. Rank hold MRNS as of Q2 2017.

  • Thompson Davis & Co reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 3,250 Marinus Pharmaceuticals, Inc shares in Q2 2017, an estimated $23K.
  • Thompson Davis & Co first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Marinus Pharmaceuticals, Inc position peaked at $23K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.